Ausgewählte Studien

Acta Derm Venereol. 2023 Mar 28;103:adv5087. doi: 10.2340/actadv.v103.5087. ABSTRACT Patients with psoriasis have a higher prevalence of cardiovascular risk factors. This study evaluated cardiovascular screening practices and statin prescribing habits among dermatologists, rheumatologists and primary care physicians (PCPs) through an online questionnaire, which was distributed through the Spanish scientific societies of the above-mentioned specialties. A total of 299 physicians (103 dermatologis

J Clin Med. 2022 Jul 26;11(15):4328. doi: 10.3390/jcm11154328. ABSTRACT BACKGROUND AND OBJECTIVES: During the last decades, growing evidence corroborates that chronic inflammatory disease impairs the body beyond the cutaneous barrier. Linkage between psoriasis and kidney disease, and in particular between psoriasis and end-stage renal disease (ESRD), have not yet been elucidated. We sought to analyze the impact of concomitant psoriasis on the in-hospital outcomes of patients hospitalized with ES

1. Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker J. Psoriasis. Lancet. (2021) 397:1301–15. doi: 10.1016/S0140-6736(20)32549-6 [PubMed] …Den ganzen Artikel lesen

Full text linksCite Display options Display options Background: Numerous observational studies have identified associations between both psoriasis (PsO) …Den ganzen Artikel lesen

Figure 1 Results of two-sample MR analysis… Figure 1 Results of two-sample MR analysis between lipid-lowering drugs and skin diseases in the… Figure …Den ganzen Artikel lesen

Skornicki M, Prince P, Suruki R, Lee E, Louder A. Skornicki M, et al. Adv Ther. 2021 May;38(5):2458-2471. doi: 10.1007/s12325-021-01698-7. Epub 2021 …Den ganzen Artikel lesen

Generalized pustular psoriasis (GPP) is a rare, inflammatory skin disease characterized by widespread eruption of sterile pustules with or without …Den ganzen Artikel lesen

Ann Rheum Dis. 2023 Feb 14:ard-2022-223499. doi: 10.1136/ard-2022-223499. Online ahead of print. ABSTRACT OBJECTIVES: To investigate factors associated with severe COVID-19 in people with psoriasis (PsO), psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA). METHODS: Demographic data, clinical characteristics and COVID-19 outcome severity of adults with PsO, PsA and axSpA were obtained from two international physician-reported registries. A three-point ordinal COVID-19 severity scale wa

Rheumatology (Oxford). 2021 Dec 13:keab901. doi: 10.1093/rheumatology/keab901. Online ahead of print. ABSTRACT OBJECTIVES: To compare demographic and clinical characteristics of patients with axial spondyloarthritis (axSpA) across geographic regions. METHODS: PROOF is an observational study that enrolled recently diagnosed (≤1 year) axSpA patients fulfilling the Assessment of SpondyloArthritis international Society classification criteria from rheumatology clinical practices in 29 countries acro

Kamila Jaworecka, Kamila Jaworecka Department of Dermatology, Institute of Medical Sciences, Medical College of Rzeszow University, Rzeszów, …Den ganzen Artikel lesen

J Dtsch Dermatol Ges. 2023 Oct;21(10):1170-1178. doi: 10.1111/ddg.15178_g. ABSTRACT HINTERGRUND UND ZIELSETZUNG: Die Psoriasisarthritis (PsA) ist eine chronische systemische Entzündungskrankheit, die den Bewegungsapparat, die Haut und die Nägel betrifft. Ziel ist es, soziodemografische und klinische Patientenprofile zu charakterisieren, die in der dermatologischen und rheumatologischen Versorgung dokumentiert werden. PATIENTEN UND METHODIK: Es wurden die Daten von 704 PsA-Patienten aus dem derma

Machado-Pinto J, Diniz Mdos S, Bavoso NC. Machado-Pinto J, et al. An Bras Dermatol. 2016 Jan-Feb;91(1):8-14. doi: 10.1590/abd1806-4841.20164169. An …Den ganzen Artikel lesen

The physiology and pathology of the skin are influenced by daily oscillations driven by a master clock located in the brain, and peripheral clocks in …Den ganzen Artikel lesen

EudraCT Number: 2022-003477-36 Sponsor Protocol Number: KKS-303 Start Date*: 2023-06-27 Sponsor Name:Justus-Liebig University Giessen - KKS …Den ganzen Artikel lesen

EudraCT Number: 2020-004081-19 Sponsor Protocol Number: 20-01/BetaSal-S Start Date*: 2021-12-22 Sponsor Name:Dermapharm AG Full Title: Double-blind, …Den ganzen Artikel lesen

The European Union Clinical Trials Register allows you to search for protocol and results information on: interventional clinical trials that are …Den ganzen Artikel lesen

The European Union Clinical Trials Register allows you to search for protocol and results information on: interventional clinical trials that are …Den ganzen Artikel lesen

EudraCT Number: 2021-001447-27 Sponsor Protocol Number: ANB019-301 Start Date*: 2021-12-08 Sponsor Name:AnaptysBio Inc. Full Title: A Phase 3, …Den ganzen Artikel lesen

EudraCT Number: 2021-004131-84 Sponsor Protocol Number: ChronIA001 Start Date*: 2022-02-14 Sponsor Name:Erasmus Medical Center Full Title: Chronotherapy …Den ganzen Artikel lesen

SummaryBackground and objectivesThe increasing use of biologics in the treatment of inflammatory diseases has led to more cases of leishmaniasis in …Den ganzen Artikel lesen

Short Paper Background: Researchers in all medical specialties increasingly use social media to educate the public, share new publications with peers, …Den ganzen Artikel lesen

Actas Dermosifiliogr. 2023 Jan 28:S0001-7310(23)00056-X. doi: 10.1016/j.ad.2023.01.004. Online ahead of print. ABSTRACT Recent years have seen concerted efforts to understand the relation between psoriasis and metabolic-associated fatty liver disease (MAFLD). Not only is MALFD diagnosed more often in patients with psoriasis, but its clinical course is also more aggressive. A common approach is therefore needed to enable early detection of liver disease coincident with psoriasis. Especially impor

WHAT IS ALREADY KNOWN ON THIS TOPIC Randomised controlled trials (RCTs) have demonstrated the efficacy and safety of ixekizumab (IXE) in the treatment …Den ganzen Artikel lesen

Full text linksCite Display options Display options Background: The psoriatic arthritis (PsA) Observational Study of Persistence of Treatment …Den ganzen Artikel lesen

Dermatol Ther (Heidelb). 2023 Dec 19. doi: 10.1007/s13555-023-01086-9. Online ahead of print. ABSTRACT INTRODUCTION: Given the chronic nature of psoriasis (PsO), more studies are needed that directly compare the effectiveness of different biologics over long observation periods. This study compares the effectiveness and durability through 12 months of anti-interleukin (IL)-17A biologics relative to other approved biologics in patients with moderate-to-severe psoriasis in a real-world setting. ME